



OBJECTIVES:

- To summarize characteristics of the direct oral anticoagulants (DOACs) currently available in Canada.
- To address common practical issues related to DOAC use.
- To address frequently asked questions regarding DOACs.

BACKGROUND:

The DOACs, which consist of apixaban, dabigatran, edoxaban, and rivaroxaban are used for the prevention and treatment of venous thromboembolism (VTE) and for stroke prevention in atrial fibrillation (AF). Practical advantages of DOACs over warfarin include fixed once- or twice-daily oral dosing without the need for coagulation test monitoring, relatively fewer known drug interactions and no known food interactions. Like warfarin, DOACs increase the risk for bleeding and should be administered under close clinical monitoring. Practical issues regarding the everyday use of DOACs will be addressed in this guide.

PRACTICAL AND LIFESTYLE ISSUES:

Can DOACs be taken with meals? Rivaroxaban should be taken with meals to enhance absorption; the tablet can be crushed and taken with soft foods such as applesauce. Apixaban, dabigatran, edoxaban can be taken with or without meals. However, taking dabigatran with meals can reduce dyspepsia. Dabigatran capsules should not be opened, broken or chewed before swallowing.

Are there any foods or beverages that need to be avoided with DOACs? Unlike with warfarin, there are no known food interactions with DOACs, so there are no food restrictions when taking these medications. In addition, there is no evidence that drinking grapefruit juice affects the effectiveness or safety of DOACs. In general, it is acceptable for patients taking a DOAC to drink alcoholic beverages in moderation (e.g. a glass of wine with a meal) as it is for patients on warfarin.

What if stomach upset occurs after starting a DOAC? Stomach upset occurs in up to 10% of patients who start dabigatran (contains tartaric acid pellets to aid absorption), but is less common with apixaban, edoxaban, or rivaroxaban. Taking dabigatran with meals can reduce the risk of stomach upset and the problem often improves on its own after a few days. Caution is advised regarding the use of antacids as the absorption of dabigatran is decreased when co-administered with antacids containing aluminum, magnesium, or calcium.

Can DOACs be placed in a dosette? Apixaban, edoxaban, and rivaroxaban can be placed in a dosette. Dabigatran needs to be kept in the medication packaging until it is taken, as there is potential for product breakdown if the capsule is exposed to moisture; it can be placed in a dosette as long as it remains sealed in its unopened blister pack.

What if a DOAC dose is missed? If a dose is missed, the next dose should *not* be doubled. Instead, it is advised to continue at the usual dose starting with the next scheduled dose. The exception is if patients are taking rivaroxaban, 15 mg twice daily, during the first 3 weeks after VTE. In this case, if a morning dose is missed, the morning dose should be taken as soon as possible so that 2 of the 15 mg tablets are taken that day. This also applies if patients are taking apixaban, 10 mg twice daily, during the first week after VTE. In this case, if a morning dose is missed, the morning dose should be taken as soon as possible so that 2 of the 10 mg tablets are taken that day.

What if the patient needs dental work? For patients who need minor dental work such as teeth cleaning or an uncomplicated tooth extraction, it is probably safe to continue the DOACs around the time of the procedure; consideration can also be given to the use of tranexamic acid mouthwash (a pro-hemostatic, antifibrinolytic agent) before and after the procedure. For the management of patients who require other procedures or surgery, see the **Clinical Guide: [NOACs/DOACs: Peri-Operative Management](#)**.

What if the patient has a prosthetic heart valve? In patients with a mechanical heart valve, DOACs are contraindicated. In patients with a bioprosthetic (tissue) heart valve, DOACs may be used as indicated for treatment of VTE or AF once the high risk period post-implantation has passed, but this has not been formally studied.

DOACs AND OTHER MEDICATIONS:

Can an NSAID be taken with DOACs? In general, long-term use of a non-steroidal anti-inflammatory drug (NSAID) combined with a DOAC should be avoided. Acetaminophen is preferred over an NSAID for joint pain, headache, or cold or flu-like symptoms. If there is a need for longer periods of treatment with an NSAID, further discussion between the patient and doctor is warranted.

Can an antacid be taken with DOACs? Absorption of dabigatran in the gastrointestinal (GI) tract requires an acid milieu. However, although the use of PPIs and H₂-blockers leads to slightly reduced bioavailability of the drug, it has no effect on clinical efficacy. Therefore, intake of these medications is not a concern with dabigatran (or with the other DOACs). Caution is advised regarding the use of antacids as the absorption of dabigatran is decreased when co-administered with antacids containing aluminum, magnesium, or calcium.

Are there other medications that should be avoided when taking a DOAC? There are certain medications that should be avoided when taking a DOAC. These are listed in **Table 1**. If one of these drugs is medically indicated over an extended duration, an alternative anticoagulant to a DOAC should be considered. Consultation with an appropriate speciality (e.g. cardiology, hematology, neurology, infectious disease) is advisable in such situations.

Can herbal medications be taken with a DOAC? Patients should avoid taking St. John's Wort if they are taking a DOAC, as this drug may reduce DOAC levels. There are no other known restrictions for other herbal medications; although, in general, those associated with an increased risk of bleeding should be avoided.

TABLE 1: KEY PROPERTIES OF DOACS

| | DABIGATRAN (PRADAXA®) | RIVAROXABAN (XARELTO®) | APIXABAN (ELIQUIS®) | EDOxabAN (LIXIANA®) |
|--|---|---|---|---|
| Clinical Indications and Doses | | | | |
| Atrial fibrillation (indefinite duration) | 150 mg or 110 mg twice daily | 20 mg or 15 mg daily | 5 mg or 2.5 mg twice daily | 60 mg or 30 mg daily |
| Acute VTE (3 to 6 months) | 150 mg twice daily (after 5-10 day course of LMWH)* | 15 mg twice daily for initial 21 days then 20 mg daily | 10 mg twice daily for initial 7 days then 5 mg twice daily | 60 mg or 30 mg daily (after 5-10 day course of LMWH)* |
| Secondary prevention of VTE | 150 mg twice daily | 20 mg daily or 10 mg daily | 5 mg or 2.5 mg twice daily | 60 mg or 30 mg daily |
| VTE prevention after knee or hip replacement surgery (14 to 30 days) | 110 mg (initial dose) then 220 mg daily | 10 mg daily | 2.5 mg twice daily | Not applicable |
| Stable coronary artery disease or peripheral artery disease | Not applicable | 2.5mg twice daily with daily low dose ASA | Not applicable | Not applicable |
| Key Pharmacologic Properties | | | | |
| Mechanism of action | Direct factor IIa (thrombin) inhibitor | Direct factor Xa inhibitor | Direct factor Xa inhibitor | Direct factor Xa inhibitor |
| Renal clearance | 80% | 33% | 25% | 50% |
| Half-life: | | | | |
| Normal to mild impairment (CrCl ≥50 mL/min) | 7-17 hours | 7-11 hours | 8-12 hours | 10-14 hours |
| Moderate renal impairment (CrCl 30-49 mL/min) | 17-20 hours | 7-11 hours | 8-12 hours | |
| Severe renal impairment (CrCl <30 mL/min) | 21-35 hours | 11-15 hours | 12-17 hours | |
| Onset of action (after oral intake) | 1-3 hours | 1-3 hours | 1-3 hours | 1-3 hours |
| Key Practical Properties | | | | |
| Food or alcohol interactions | None | Needs to be taken with food | None | None |
| Drug Interactions | | | | |
| Substrate of P-gp | Yes | Yes | Yes | Yes |
| Substrate of CYP3A4 | No | Yes (~18%) | Yes (~25%) | No |
| Examples of medications that INCREASE levels | amiodarone, dronedarone, cyclosporine, quinidine, azole | azole antifungals (e.g. ketoconazole, itraconazole, voriconazole, and | azole antifungals (e.g. ketoconazole, itraconazole, voriconazole, | Cyclosporine, dronedarone, quinidine, azole antifungals (e.g. |

| | DABIGATRAN (PRADAXA®) | RIVAROXABAN (XARELTO®) | APIXABAN (ELIQUIS®) | EDOXABAN (LIXIANA®) |
|--|--|--|--|--|
| | antifungals (e.g. ketoconazole, itraconazole, posaconazole), and HIV protease inhibitors (eg. ritonavir) | posaconazole), HIV protease inhibitors (e.g. ritonavir), and macrolide antibiotics (e.g. clarithromycin) | posaconazole), HIV protease inhibitors (e.g. ritonavir), macrolide antibiotics (e.g. clarithromycin) | ketoconazole, itraconazole,), HIV protease inhibitors (e.g. ritonavir), macrolide antibiotics (e.g. clarithromycin) |
| Examples of medications that DECREASE levels | rifampin, carbamazepine, phenytoin, and St. John's Wort | anticonvulsants (e.g. phenytoin, carbamazepine), rifampin and St. John's Wort | anticonvulsants (e.g. phenytoin, carbamazepine), rifampin and St. John's Wort likely | anticonvulsants (e.g. phenytoin, carbamazepine), rifampin and St. John's Wort |
| Antidote | Idarucizumab | Andexanet alfa (not yet approved by Health Canada) | Andexanet alfa (not yet approved by Health Canada) | Andexanet alfa (not yet approved by Health Canada) |

*dabigatran and edoxaban require an initial 5-10 day course of LMWH before they are started (see the **Clinical Guides: Deep Vein Thrombosis (DVT): Treatment and Pulmonary Embolism (PE): Treatment**).

MONITORING AND FOLLOW-UP OF PATIENTS TAKING A DOAC:

Do patients taking a DOAC need routine clinical follow-up? Yes. It is prudent to perform routine follow-up at least every 6-12 months in patients who are receiving long-term treatment with a DOAC. This is required to confirm the patient has an ongoing indication for DOAC, check for bleeding complications, assess the relative risks of thromboembolism and bleeding complications, assess kidney function and conduct an updated medication review (prescription, over-the-counter, herbal supplements). These factors may warrant adjustment of the DOAC dose, change from one DOAC to another DOAC, or change from a DOAC to warfarin. In addition, periodic follow-up is useful to check for patient compliance with their DOAC treatment, and to plan for treatment interruptions for upcoming procedures.

Do patients taking a DOAC need routine coagulation testing? No. Tests of coagulation such as the INR or aPTT do not need to be done routinely in patients who are receiving a DOAC. However, DOACs can variably affect these blood tests; cautious and informed interpretation is needed if these tests are done for other reasons (e.g. before surgery). A summary of the effect of DOACs on coagulation tests is shown in **Table 2**. (See also the **Clinical Guides: [NOACs/DOACs: Coagulation Tests](#) and [NOACs/DOACs: Peri-Operative Management](#)**).

Do patients taking a DOAC need any routine blood testing? Yes. It is prudent for patients who are receiving a DOAC to have an assessment of kidney function, hemoglobin and platelet count every 6-12 months and with any acute medical illness, since worsening of renal function may warrant a change in the dose of a DOAC, switching from one DOAC to another, or switching from a DOAC to warfarin. A decrease in hemoglobin may indicate occult bleeding.

How does one switch from warfarin to a DOAC? After stopping warfarin, the patient should wait until the INR is less than 2.0 before starting dabigatran or apixaban and less than or equal to 2.5 for rivaroxaban and edoxaban. This is because the onset of action of the DOAC is rapid (peak effect

1-3 hours after ingestion), while the offset of action of warfarin is slower. If INR testing is not readily available, it is reasonable to wait 2-3 days after the last dose of warfarin before starting a DOAC. Note, if the INR is supratherapeutic, it will take longer to achieve an INR or 2.0 or lower.

TABLE 2: SUMMARY OF TESTING FOR MEASUREMENT OF DOAC ANTICOAGULANT EFFECT[†]

| | DABIGATRAN (PRADAXA [®]) | RIVAROXABAN (XARELTO [®]) | APIXABAN (ELIQUIS [®]) | EDOXABAN (LIXIANA [®]) |
|------------------------------|--|--|----------------------------------|--|
| aPTT | Nonlinear prolongation with increasing dose, a normal result does not exclude an important drug effect | Minimal effect | Minimal effect | Variable effect; a normal result does not exclude an important drug effect |
| Thrombin clotting time (TCT) | Normal result excludes detectable residual anticoagulant effect | No effect | No effect | No effect |
| Dilute TCT | dilute TCT (Hemoclot assay) most reliable/accurate | | | |
| PT/INR | Variable effect | Variable effect; a normal result does not exclude an important drug effect | Minimal effect | Variable effect; a normal result does not exclude an important drug effect |
| anti-factor Xa assay | No effect | Most reliable/accurate | Most reliable/accurate | Most reliable/accurate |

[†]Laboratory tests may not reliably reflect levels of anticoagulation with DOACs and the routinely available tests should not be used for this purpose (See the Clinical Guide: [NOACs/DOACs: Coagulation Tests](#)).

ACUTE MEDICAL EMERGENCIES IN PATIENTS RECEIVING A DOAC:

What if my patient has an acute ischemic stroke? In patients who have an acute stroke and are receiving a DOAC, the management should be similar to other patients with an ischemic stroke. In general, compliance with the DOAC should be assessed. Where appropriate, thrombolytic therapy should be considered, especially if sufficient time has elapsed since the last DOAC dose such that there would be little residual anticoagulant effect. Note that a normal aPTT and/or INR/PT cannot be used as reassurance that intravenous thrombolysis can be safely given to patients with acute ischemic stroke. There is currently no consensus about when intravenous thrombolysis can be safely administered in patients on DOACs. In the emergent setting of stroke thrombolysis, the best tool to determine when the last DOAC dose was taken remains the clinical history. Consultation

with a neurologist is strongly advised in these situations. (See the **Clinical Guide: [Stroke Thrombolysis and Endovascular Therapy](#)**).

What if my patient has an acute coronary syndrome? In patients who are receiving a DOAC and suffer an acute coronary syndrome, the management should be similar to other patients with such an event. Consultation with a cardiologist is strongly advised in these situations. (See also the **Clinical Guide: [Anticoagulation in Patients Requiring Antiplatelet Therapy](#)**).

What if my patient has major trauma or a serious bleed? In such patients, emphasis should be on supportive care and treating the underlying cause of bleeding (See the **Clinical Guide: [NOACs/DOACs: Management of Bleeding](#)**). In selected circumstances for patients on dabigatran, administration of the antidote idarucizumab may be considered. Consultation with a hematologist or thrombosis specialist is advised in these situations.

COMPARISON OF DOACs:

Are there any studies comparing the DOACs? There are no “head-to-head” randomized trials comparing the different DOACs. All the studies done to date have compared one DOAC with warfarin for stroke prevention in AF and for the treatment of VTE, or with LMWH for VTE prophylaxis and for the treatment of cancer-associated thrombosis.

Which DOAC is the most effective and which is the safest in patients with AF? This is currently impossible to answer because the randomized trials comparing each DOAC to warfarin (INR 2.0-3.0) for stroke prevention in AF differed in terms of trial design, patient population studied, and medication dose regimens used. Each DOAC has potential advantages and drawbacks. Choosing which of these drugs is best for your patient should include an assessment of 1) your patient’s risk profile for stroke; 2) your patient’s risk profile for bleeding; and 3) the presence of comorbid conditions (e.g. prior stroke, renal dysfunction).

Which DOAC is the most effective and which is the safest in patients with acute VTE? As with AF, there are no “head-to-head” trials comparing the DOACs for the treatment of acute VTE.

How should DOACs be used in patients with impaired renal function? The DOACs differ in terms of how they should be used in patients who have impaired renal function. **Table 3** provides a suggested guide for using DOACs in patients with AF and impaired renal function. Note there is no dose reduction for renal impairment for the acute treatment of VTE.

TABLE 3: SUGGESTED USE OF DOACs ACCORDING TO PATIENT RENAL FUNCTION FOR STROKE PREVENTION IN AF[‡]

| DOAC | CrCl (mL/min) | DRUG DOSE | COMMENT |
|------------|---------------|---------------------------|--|
| Dabigatran | ≥ 50 | 110 or 150 mg twice daily | Consider 110 mg dose in patients at increased risk for bleeding or in the elderly (e.g. age ≥ 80 years or ≥ 75 years with additional bleeding risk factors) Measure CrCl every 12 months |
| | 30-49 | 110 or 150 mg twice daily | Consider 110 mg dose in patients at increased risk for bleeding (e.g. age ≥ 80 years or ≥ 75 years with additional bleeding risk factors) Measure CrCl every 6 months <i>and</i> with acute illness |

| | | | |
|--------------------|-------|-------------------------------------|---|
| | | | Consider avoiding if deteriorating renal function |
| | < 30 | Avoid dabigatran | Consider warfarin as an alternative anticoagulant |
| Rivaroxaban | ≥ 50 | 20 mg daily | Measure CrCl every 12 months |
| | 30-49 | 15 mg daily | Measure CrCl every 6 months <i>and</i> with acute illness Consider avoiding if deteriorating renal function |
| | 15-30 | 15 mg daily approved | Use with caution due to limited clinical data; if used, measure CrCl every 3 months <i>and</i> with acute illness Consider warfarin as alternative anticoagulant |
| | < 15 | Avoid rivaroxaban | Consider warfarin as an alternative anticoagulant |
| Apixaban | ≥ 50 | 5 mg twice daily | 2.5 mg twice daily in patients with 2 of following: (1) creatinine ≥ 133 µmol/L; (2) age ≥ 80 years; (3) body weight ≤ 60 kg Measure CrCl every 12 months |
| | 25-49 | 5 mg twice daily | 2.5 mg twice daily in patients with 2 of following: (1) creatinine ≥ 133 µmol/L; (2) age ≥ 80 years; (3) body weight ≤ 60 kg Measure CrCl every 6 months <i>and</i> with acute illness |
| | 15-24 | No dose recommendations can be made | Very limited clinical data Consider warfarin as alternative anticoagulant |
| | < 15 | Avoid apixaban | Consider warfarin as an alternative anticoagulant |
| Edoxaban | ≥50 | 60 mg daily | Reduce dose to 30 mg daily if weight <60 kg or if concomitant use of P-gp inhibitor (except amiodarone and verapamil). Measure CrCl every 12 months. |
| | 30-50 | 30 mg daily | Measure CrCl every 6 months <i>and</i> with acute illness Consider avoiding if deteriorating renal function |
| | <30 | Avoid edoxaban | Consider warfarin as an alternative anticoagulant |

‡It is advised to consult with a specialist if there is uncertainty about the appropriate DOAC drug and dose regimen and if warfarin provides a better oral anticoagulation option for individual patients.

OTHER RELEVANT GUIDES:

- Anticoagulation in Patients Requiring Antiplatelet Therapy
- Apixaban (Eliquis®)
- Dabigatran (Pradaxa®)
- Deep Vein Thrombosis (DVT): Treatment
- Edoxaban (Lixiana®)
- NOACs/DOACs: Coagulation Tests
- NOACs/DOACs: Management of Bleeding
- NOACs/DOACs): Peri-Operative Management
- Pulmonary Embolism (PE): Diagnosis
- Pulmonary Embolism (PE): Treatment
- Rivaroxaban (Xarelto®)
- Stroke Prevention in Atrial Fibrillation

- Stroke Thrombolysis and Endovascular Therapy
- Thromboprophylaxis: Orthopedic Surgery

*NOACs/DOACs = Non-vitamin K antagonist Oral AntiCoagulants, also known as Direct Oral AntiCoagulants

REFERENCES:

Ang Li, et al. Direct oral anticoagulant versus low-molecular-weight heparin for treatment of cancer associated thrombosis: A systematic review and meta-analysis. *Thrombosis Research* 2019;173:158-163

Eikelboom JW, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. *N Engl J Med* 2017;377(14):1319-1330

Ruff CT, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014;383(9921):955-962.

Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. *Blood* 2012;119(13):3016-3023.

Steffel, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *Eur Heart J* 2018;39:1330-1393.

van der Hulle T, et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. *J Thromb Haemost* 2014;12(3):320-328.

Date of Version: 16Feb2020

Please note that the information contained herein is not to be interpreted as an alternative to medical advice from your doctor or other professional healthcare provider. If you have any specific questions about any medical matter, you should consult your doctor or other professional healthcare providers, and as such you should never delay seeking medical advice, disregard medical advice or discontinue medical treatment because of the information contained herein.